This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.This deal, advised by Guggenheim Securities, is part of Pfizer’s strategy to boost its specialty medicine segment.